ClinicalTrials.gov
ClinicalTrials.gov Menu

Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00245310
Recruitment Status : Completed
First Posted : October 27, 2005
Last Update Posted : October 11, 2010
Sponsor:
Information provided by:
Heidelberg University

Brief Summary:

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.

The ICG-clearance will be evaluated as a prognostic marker in liver disease.


Condition or disease Intervention/treatment
Acute Liver Failure Liver Cirrhosis Procedure: Indocyangreen (ICG) clearance

Detailed Description:
patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure
Study Start Date : October 2005
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Criteria

Inclusion Criteria:

  • acute liver failure OR end-stage liver disease
  • normal hepatic perfusion by doppler ultrasound

Exclusion Criteria:

  • portal vein thrombosis
  • allergy to ICG or iodine
  • thyroid disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245310


Locations
Germany
University of Heidelberg
Heidelberg, Germany, 69120
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Jens Encke, PD Dr. med. Heidelberg University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00245310     History of Changes
Other Study ID Numbers: LiMON
First Posted: October 27, 2005    Key Record Dates
Last Update Posted: October 11, 2010
Last Verified: November 2008

Keywords provided by Heidelberg University:
ICG clearance
liver cirrhosis
acute liver failure
prognosis

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Liver Failure
Liver Failure, Acute
Pathologic Processes
Liver Diseases
Digestive System Diseases
Hepatic Insufficiency